Wyeth Pharmaceutical Co. Ltd., a prominent player in the global pharmaceutical industry, is headquartered in China (CN) and operates extensively across Asia and beyond. Founded in the early 20th century, the company has achieved significant milestones, establishing itself as a leader in innovative healthcare solutions. Specialising in a diverse range of therapeutic areas, Wyeth focuses on biologics, vaccines, and prescription medications, with a commitment to improving patient outcomes. Its core products are distinguished by their advanced formulations and rigorous research and development processes, ensuring high efficacy and safety standards. With a strong market position, Wyeth Pharmaceutical Co. Ltd. is recognised for its contributions to public health and has garnered numerous accolades for its pioneering work in pharmaceuticals. The company continues to drive advancements in medicine, reinforcing its reputation as a trusted name in the healthcare sector.
How does Wyeth Pharmaceutical Co. Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Wyeth Pharmaceutical Co. Ltd's score of 79 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Wyeth Pharmaceutical Co. Ltd, headquartered in China (CN), currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Haleon plc, which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, Wyeth Pharmaceutical has not publicly outlined any specific reduction targets or initiatives. However, it is important to note that the climate commitments and performance metrics may be influenced by Haleon plc's sustainability strategies, which include various initiatives aimed at reducing carbon emissions across their operations. Given the absence of direct emissions data, stakeholders should look to Haleon plc for insights into the broader climate strategies and performance metrics that may impact Wyeth Pharmaceutical's environmental footprint.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 59,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 37,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 
Wyeth Pharmaceutical Co. Ltd's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 7% since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 59% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Wyeth Pharmaceutical Co. Ltd has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.